2 completed, 1 enrolling by invitation, 1 recruiting. 4 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Enrolling by invitation 1, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Delusions: new trials by email Literature Review of Delusions trials Research Report on Delusions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study ACP-204 - Alzheimer's Disease Psychosis | Phase 3 | Enrolling by invitation | ACADIA Pharmaceuticals Inc. | 752 | 2024-04-23 | 2026-08-05 |
| ACP-204 in Adults With Alzheimer's Disease Psychosis ACP-204, Placebo - Alzheimer's Disease Psychosis | Phase 2 / Phase 3 | Recruiting | ACADIA Pharmaceuticals Inc. | 1074 | 2023-11-14 | 2026-10-19 |
| Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg - Dementia-related Psychosis | Phase 3 | Completed | ACADIA Pharmaceuticals Inc. | 392 | 2017-09-27 | 2021-06-21 |
| Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants Ethyl-eicosapentaenoic acid (EPA), Vitamins E + C, Etyl EPA (placebo) - Schizophrenia, Schizophreniform Disorders | Phase 2 / Phase 3 | Completed | University Hospital, Aker | 99 | 2001-09-01 | 2011-01-04 |
Hallucinations (4) · Psychotic Disorders (2) · Alzheimer Disease (1) · Corticobasal Degeneration (1) · Dementia (1) · Dementia, Vascular (1) · Hypertriglyceridemia (1) · Lewy Body Disease (1) · Schizophrenia (1) · Supranuclear Palsy, Progressive (1)
Behavior (4) · Behavioral Symptoms (4) · Nervous System Diseases (4) · Neurobehavioral Manifestations (4) · Neurologic Manifestations (4) · Pathological Conditions, Signs and Symptoms (4) · Perceptual Disorders (4) · Signs and Symptoms (4) · Mental Disorders (2) · Schizophrenia Spectrum and Other Psychotic Disorders (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Basal Ganglia Diseases (1) · Brain Diseases (1) · Cardiovascular Diseases (1)
eicosapentaenoic acid ethyl ester (1) · pimavanserin (1)
ACADIA Pharmaceuticals Inc. (3) · University Hospital, Aker (1)
Bulgaria (3) · Chile (3) · Czechia (3) · France (3) · Italy (3) · Serbia (3) · Spain (3) · United States (3) · Brazil (2) · Mexico (2) · South Korea (2) · Taiwan (2) · Germany (1) · Norway (1) · Poland (1)
PMID 34289275, PMID 34934801, PMID 41286676
2017 (1)